All In Biotech

Drug Trial Radar · NCT07318909

To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria

A Clinical Exploration Study of Adeno-Associated Virus Vector Expressing Human Phenylalanine Hydroxylase Gene in Adult Classical Phenylketonuria

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Dec 31, 2027

Primary completion

Dec 31, 2028

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Gritgen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, open-label, dose-escalation, exploratory study to evaluate the safety, tolerability, and efficacy of a single administration of GS1168 Injection in Chinese adult phenylketonuria (PKU) with PAH mutation.

Conditions

  • Phenylketonuria (PKU)

Interventions

  • GS1168 injectionDrug

    The dose levels are as follows: 1. A single intravenous administration of GS1168 injection at dose level 1; 2. A single intravenous administration of GS1168 injection at dose level 2; 3. A single intravenous administration of GS1168 injection at dose level 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse event (AE), including serious adverse event (SAE) and adverse event of special interest (AESI)Time frame: Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.